GRAIL, Inc. Common Stock — États financiers trimestriels (NASDAQ:GRAL)

Afficher le graphique complet

Financials

Aperçu Relevé Statistiques

Trimestriel Annuel

Market Capitalization 2.1359 B
Employee 910
Founded 2015
CEO N/A
Website www.grail.com
Headquarter Delaware, United States
FIGI BBG01N6CGW43
Industry Diagnostic et Recherche

Chiffre d'affaires total

Résultat net

Bénéfice par action de base (BPA de base)

Dette totale

Flux de trésorerie disponible

Trésorerie et équivalents de trésorerie

2.14 B Capitalisation boursière

ratio cours/bénéfice

-7.7

ratio cours/chiffre d'affaires

21.37

GRAIL Inc

GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021. In June 2021 GRAIL launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023 EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024.